Monday that U.S. and Canadian regulators have authorized the use of
its Ebola treatment in patients who have confirmed or suspected
infections from the deadly virus.
The Vancouver-based company said its treatment, TKM-Ebola, has been
administered to patients on an emergency basis and the repeat
infusions have been well-tolerated.
Expanded access protocols, authorized by the U.S. Food and Drug
Administration and Health Canada, allow drug developers to offer
experimental therapies to patients with serious diseases who cannot
participate in controlled clinical trials.
Tekmira Chief Executive Officer Mark Murray said the company's
supplies of the treatment are limited.
The company is developing TKM-Ebola under a contract with the U.S.
Department of Defense.
Tekmira shares rose 6 percent in Toronto and 9 percent on the Nasdaq.
No comments:
Post a Comment